Accueil   Diary - News   All news Tollys receives over €1.5 million deep tech financing from Bpifrance

Tollys receives over €1.5 million deep tech financing from Bpifrance

Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer.


Lyon, France, July 6, 2020 – Tollys, the developer of TL-532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, today announces it has received over €1.5 million ($1.6M) from Bpifrance as part of its deep tech financing program. This program aims to increase support measures for breakthrough innovation in France and to strengthen the country’s competitive advantage in the field.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree